{"gene":"LOX","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2016,"finding":"LOX catalytic domain mutations (p.Ser280Arg and p.Ser348Arg) result in significantly lower lysyl oxidase enzymatic activity compared to wild-type protein, and LOX haploinsufficiency predisposes to thoracic aortic aneurysms and dissections, placing LOX as a causal component of aortic structural integrity via its collagen/elastin cross-linking activity.","method":"Exome sequencing to identify variants, functional assay of lysyl oxidase enzymatic activity for mutant vs. wild-type protein, segregation analysis in families","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct enzymatic activity assay of disease-causing mutants with multiple independent families and genetic segregation evidence","pmids":["26838787"],"is_preprint":false},{"year":2020,"finding":"LOX, induced by hypoxia, promotes chemoresistance in triple-negative breast cancer by cross-linking collagen and assembling fibronectin in the ECM; LOX inhibition reduces collagen cross-linking and fibronectin assembly, decreases drug penetration barrier, downregulates ITGA5/FN1 expression, and inhibits FAK/Src signaling, leading to apoptosis and chemosensitization.","method":"LOX inhibition/knockdown in 3D cell lines, tumor organoids, xenografts, syngeneic tumors, and PDX models; RNA-sequencing; miR-142-3p re-expression targeting HIF1A/LOX/ITGA5 axis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal models (organoids, xenografts, PDX), mechanistic pathway placed with epistasis (LOX→ITGA5/FN1→FAK/Src), replicated across systems","pmids":["32415208"],"is_preprint":false},{"year":2003,"finding":"LOX (lysyl oxidase) is a copper-dependent amine oxidase that requires a conserved copper binding site, lysyl and tyrosyl residues contributing to quinone cofactor formation, and a cytokine receptor-like domain for function; the N-terminal propeptide domain confers unique regulatory properties distinct from the catalytic C-terminal domain.","method":"Structural/domain analysis, comparative expression and sequence analysis across LOX family members including Drosophila orthologs; BMP-1 processing assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — domain mapping and comparative analysis without full mutagenesis reconstitution; consistent across family members","pmids":["12686136"],"is_preprint":false},{"year":2019,"finding":"HIF2A (but not HIF1A) directly induces LOX expression to promote collagen cross-linking and fibrotic ECM deposition in orbital fibroblasts; inhibition of HIF2A or LOX (by shRNA or small molecule antagonists) ameliorated fibrosis in 3D organoids, and constitutively active HIF2A was sufficient to initiate LOX-dependent fibrotic remodeling.","method":"shRNA knockdown, small molecule inhibitor experiments, HIF2A overexpression in 3D organoid cultures of human orbital fibroblasts, validated in human TAO tissues","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (HIF2A→LOX→fibrosis), multiple orthogonal approaches (shRNA, overexpression, pharmacological inhibition) in a single lab","pmids":["30388216"],"is_preprint":false},{"year":2016,"finding":"LOX transcriptionally activates the SNAI2 promoter (demonstrated by chromatin immunoprecipitation and promoter luciferase assays), and the LOX/SNAI2 axis regulates TIMP4 secretion, thereby mediating epithelial-to-mesenchymal transition and cancer progression.","method":"Chromatin immunoprecipitation (ChIP), promoter luciferase assays, siRNA knockdown, in vivo metastatic mouse model of thyroid cancer, protein arrays for MMPs/TIMPs, IHC on patient samples","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct ChIP and promoter assay establish LOX binding to SNAI2 promoter; multiple orthogonal methods (ChIP, luciferase, in vivo model) in single lab","pmids":["27029493"],"is_preprint":false},{"year":2009,"finding":"A SNP (G473A; Arg158Gln) in the LOX propeptide domain (LOX-PP) profoundly impairs the ability of LOX-PP to inhibit tumor invasion and xenograft tumor formation, identifying the propeptide as the tumor suppressor domain of LOX and demonstrating that the Gln variant cannot oppose LOX enzymatic activity-promoted invasion.","method":"Xenograft tumor formation assays, invasion assays comparing Arg158 vs Gln158 LOX-PP variants, comparison of LOX-PP vs. LOX enzymatic effects on invasive phenotype","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional mutagenesis (Arg→Gln substitution) with in vivo xenograft assay and in vitro invasion assay establishing LOX-PP as tumor suppressor domain","pmids":["19654310"],"is_preprint":false},{"year":2014,"finding":"LOX promotes RANKL expression in bone marrow stromal cells via production of reactive oxygen species (ROS), which indirectly stimulates osteoclastogenesis; however, LOX cannot substitute for RANKL and does not induce osteoclast differentiation in RANKL-deficient or RANK-deficient cells.","method":"In vitro osteoclastogenesis assays with wild-type, RANKL-KO, and RANK-KO cells; LOX injection in RANKL-deficient mice; TRAP staining; resorption pit assays","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis using KO cells and animals, multiple cell types; clearly defines LOX mechanism (ROS→RANKL induction) and its limits (cannot replace RANKL)","pmids":["27606829"],"is_preprint":false},{"year":2009,"finding":"LOX gene deficiency in osteoblasts reduces DNA synthesis, impairs mineral nodule formation, and markedly decreases osteoblastic differentiation markers (type I collagen, bone sialoprotein, Runx2/Cbfa1), establishing a role for LOX in osteoblast phenotype beyond extracellular collagen cross-linking.","method":"Primary calvarial osteoblasts from Lox(-/-) knockout mice; DNA synthesis assays; annexin-V apoptosis assays; RT-PCR and immunostaining for differentiation markers","journal":"Calcified tissue international","confidence":"High","confidence_rationale":"Tier 2 / Moderate — LOX KO primary cells with multiple phenotypic readouts; clean loss-of-function with defined cellular phenotype","pmids":["19458888"],"is_preprint":false},{"year":2019,"finding":"LOX intramembrane proteolysis by SPPL2a/b controls atherogenic LOX-1 (OLR1) signaling: ADAM10 sheds the LOX-1 ectodomain generating N-terminal fragments (NTFs) that self-associate via their transmembrane domains and activate MAP kinases in a ligand-independent manner, upregulating ICAM-1 and CTGF; SPPL2a/b deficiency causes NTF accumulation, enlarging atherosclerotic plaques.","method":"Identification of ADAM10 shedding and SPPL2a/b substrates by biochemical assays; MAP kinase activation assays; SPPL2a/b-deficient mouse atherosclerosis models; transmembrane domain self-association experiments","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic dissection of LOX-1 proteolytic processing with KO mice, substrate identification, and defined signaling consequences; multiple orthogonal methods","pmids":["30819724"],"is_preprint":false},{"year":2006,"finding":"LOX-1 (OLR1) recognizes phosphatidylserine (PS) in a Ca2+-dependent manner; recombinant glycosylated LOX-1 binds PS but not other phospholipids, and this recognition is maximal with millimolar Ca2+ but not Mg2+; LOX-1-mediated recognition of PS-containing apoptotic bodies is blocked by bivalent-cation chelation or LOX-1-blocking antibodies.","method":"In vitro binding assays with recombinant glycosylated LOX-1; cell-based PS recognition assays; Ca2+/Mg2+ substitution; blocking antibodies; PS-containing liposome competition","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro binding with recombinant protein, Ca2+ specificity demonstrated by ion substitution, validated in cells with blocking antibodies","pmids":["16146427"],"is_preprint":false},{"year":2020,"finding":"HRD1 (E3 ubiquitin ligase) directly interacts with LOX-1 and promotes its ubiquitination and proteasomal degradation; KLF2 transcription factor positively regulates HRD1 expression, and decreased HRD1 leads to LOX-1 accumulation and endothelial apoptosis; LOX-1 deletion attenuated apoptosis caused by HRD1 downregulation.","method":"Co-immunoprecipitation (HRD1-LOX-1 interaction), ubiquitination assay, proteasome inhibitor experiments, KLF2 promoter binding assay, HRD1 overexpression/knockdown in endothelial cells, LOX-1 deletion epistasis","journal":"Cell cycle","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing interaction, ubiquitination assay confirming PTM (ubiquitination), epistasis (LOX-1 KD rescues HRD1-KD phenotype), single lab","pmids":["32308114"],"is_preprint":false},{"year":2015,"finding":"Statins directly interact with the C-type lectin-like (CTLD) recognition domain of LOX-1, filling the hydrophobic tunnel and stabilizing the LOX-1 dimer assembly; this mechanism underlies statin-mediated inhibition of ox-LDL binding to LOX-1 independent of cholesterol lowering.","method":"Cell-based fluorescent ox-LDL displacement binding assay, molecular docking simulations, molecular dynamics simulation, electrophoretic separation and western blot for dimer stabilization","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — cell-based binding assay and structural modeling with biochemical validation of dimer stabilization; computational plus experimental, single lab","pmids":["25950192"],"is_preprint":false},{"year":2003,"finding":"High glucose induces LOX-1 expression in human aortic endothelial cells at the transcriptional level through increased oxidant stress and activation of NF-κB, PKC, and MAPK signaling; LOX-1 upregulation mediates high glucose-induced monocyte adhesion to endothelium.","method":"RT-PCR, protein expression, EMSA (NF-κB binding to LOX-1 promoter), pharmacological inhibitors of NF-κB/PKC/MAPK, anti-LOX-1 antibody blocking monocyte adhesion","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Moderate — EMSA demonstrates transcription factor binding to LOX-1 promoter; multiple pathway inhibitors with functional readout (monocyte adhesion), single lab","pmids":["12829655"],"is_preprint":false},{"year":2001,"finding":"LOX-1 is expressed in human platelets (mRNA and protein) and is stored intracellularly, becoming surface-exposed in an activation-dependent manner; activated platelet LOX-1 mediates ox-LDL binding, and accumulates at thrombus sites in atherosclerotic plaques.","method":"RT-PCR, protein detection, flow cytometry on activated vs. resting platelets, anti-LOX-1 antibody blocking of ox-LDL binding, immunohistochemistry of atherosclerotic plaque","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — flow cytometry documenting activation-dependent surface translocation; antibody blocking of function; consistent across cell lines and primary platelets","pmids":["11263985"],"is_preprint":false},{"year":2011,"finding":"microRNA let-7g negatively regulates LOX-1 expression via a binding site in the 3'-UTR of LOX-1 mRNA; ox-LDL reduces let-7g expression through a Ca2+-activated PKC pathway; OCT-1 represses let-7g promoter activity; let-7g overexpression inhibits ox-LDL-induced LOX-1/OCT-1 expression and cell proliferation and migration.","method":"3'-UTR luciferase reporter assay confirming let-7g binding site, promoter assay for OCT-1 binding to let-7g promoter, chromatin immunoprecipitation (ChIP), transfection of let-7g mimics/inhibitors, Ca2+/PKC inhibitor studies","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — luciferase reporter establishes direct miRNA binding to LOX-1 3'-UTR; ChIP validates OCT-1 binding; multiple orthogonal methods in single lab","pmids":["22135361"],"is_preprint":false},{"year":2014,"finding":"LOX-1 activation in macrophages drives ROS generation, mitochondrial DNA damage, and autophagy, which together activate the NLRP3 inflammasome; LOX-1 inhibition (antibody or siRNA) suppresses ROS, autophagy, mtDNA damage, and NLRP3 activation; DNase II knockdown inhibits autophagy and NLRP3 inflammasome downstream of damaged mtDNA.","method":"LOX-1 siRNA/antibody inhibition in THP-1 macrophages and primary macrophages, ROS inhibitors, autophagy inducer/inhibitor, DNase II knockdown, NLRP3 inflammasome activation assays","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — epistasis established with multiple genetic and pharmacological interventions; pathway defined (LOX-1→ROS→mtDNA damage→autophagy→NLRP3); replicated in primary and cell line models","pmids":["24776598"],"is_preprint":false},{"year":2015,"finding":"LOX (lysyl oxidase) and PCSK9 positively regulate each other's expression in vascular cells; siRNA knockdown of PCSK9 reduces LOX-1 expression and function; LOX-1 knockdown reduces PCSK9 expression; LOX-1 KO mice express less PCSK9 and PCSK9-KO mice express less LOX-1; mitochondrial ROS initiates this mutual regulation, acting upstream of both.","method":"siRNA transfection (PCSK9 and LOX-1 knockdown), recombinant hPCSK9 treatment, LOX-1 cDNA overexpression, LOX-1 and PCSK9 KO mouse studies, mtROS induction/inhibition","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal siRNA knockdown, KO mouse models for both genes, and pharmacological epistasis with mtROS; multiple orthogonal approaches","pmids":["26092101"],"is_preprint":false},{"year":2001,"finding":"Statins (simvastatin, atorvastatin) reduce ox-LDL-induced LOX-1 upregulation and simultaneously prevent LOX-1-mediated suppression of eNOS expression; LOX-1 activation by ox-LDL also activates MAP kinase, and statin attenuation of MAP kinase provides a mechanism for eNOS restoration.","method":"Human coronary artery endothelial cells treated with ox-LDL ± statins; LOX-1 and eNOS expression by western blot; MAP kinase activation assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — single lab, single cell type, dose-response data; places LOX-1→MAP kinase→eNOS in a signaling pathway but limited mechanistic depth","pmids":["11735125"],"is_preprint":false},{"year":2000,"finding":"TGF-β1 differentially regulates scavenger receptors in human macrophages: it decreases CD36 and SR-A expression while upregulating LOX-1 mRNA, thereby altering the balance of modified LDL uptake and foam cell formation.","method":"RT-PCR and flow cytometry in THP-1 cells and primary human monocytes treated with TGF-β1; measurements of scavenger receptor expression and total ox-LDL uptake","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — RT-PCR and protein expression in both cell line and primary human cells; multiple scavenger receptors compared as controls","pmids":["10749696"],"is_preprint":false},{"year":2014,"finding":"LOX inhibition (by BAPN) in glioblastoma cell lines reduces migration, invasion, and soft agar colony formation; LOX protein localizes to cytoplasm and nucleus, with nuclear localization being lower in IDH1-mutant glioblastoma.","method":"siRNA knockdown and BAPN pharmacological inhibition of LOX in U87MG and A172 glioblastoma cell lines; migration, invasion, and colony formation assays; immunohistochemistry for subcellular localization","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — functional assays (migration, invasion) with both genetic and pharmacological LOX inhibition; single lab, single cell type pair","pmids":["25790191"],"is_preprint":false},{"year":2014,"finding":"miR30a directly targets and represses LOX expression (identified as a direct target via miRNA target prediction validated experimentally); LOX inhibition decreases cellular invasion, migration, EMT marker levels, and metastatic capacity in thyroid cancer models in vitro and in vivo.","method":"miR30a mimic/inhibitor transfections, LOX expression analysis, in vitro invasion/migration assays, in vivo metastasis model; LOX identified as direct miR30a target","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — functional assays in vitro and in vivo; direct miRNA-LOX targeting established; single lab but in vivo validation included","pmids":["25488748"],"is_preprint":false},{"year":2020,"finding":"Th17 cells promote LOX expression via the IL-17/ERK1/2-AP-1 signaling pathway, while Tregs inhibit LOX expression via the IL-10/JAK1-STAT3 pathway; LOX upregulation mediates increased collagen cross-linking and myocardial fibrosis in cardiac fibroblasts.","method":"Co-culture of cardiac fibroblasts with polarized Th17/Treg cells; BAPN LOX inhibitor; signaling pathway inhibitors; adoptive transfer in HF rat model; LOX expression and collagen deposition measurements","journal":"Acta physiologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models; specific signaling pathways identified for both Th17 and Treg regulation of LOX; single lab","pmids":["32649012"],"is_preprint":false},{"year":2024,"finding":"LOX-mediated ECM cross-linking increases tissue stiffness, which activates mechanosensitive Piezo1 channels in neurons; Piezo1 activation induces ferroptosis in a GPX4-dependent manner in hypoxic-ischemic brain damage; pharmacological LOX inhibition with traumatic acid (identified as a novel LOX inhibitor) reduces neuronal ferroptosis and improves neurological outcomes.","method":"LOX activity measurement in HIBD models in vivo and in vitro, ECM stiffness assays, Piezo1 expression/activation analysis, LOX/Piezo1 pharmacological inhibition, LOX inhibitor (traumatic acid) enzymatic activity assay, ferroptosis markers (GPX4), behavioral testing","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway (LOX→ECM stiffness→Piezo1→ferroptosis) defined with pharmacological interventions at multiple steps; in vitro and in vivo; single lab","pmids":["39260063"],"is_preprint":false},{"year":2003,"finding":"LOX-1 pathway activation in cardiomyocytes following ischemia-reperfusion (but not ischemia alone) contributes to myocardial infarction; anti-LOX-1 monoclonal antibody treatment reduced myocardial infarction size by ~50% in a rat coronary artery ligation/reperfusion model.","method":"Rat ischemia-reperfusion model; immunohistochemistry for LOX-1 induction in cardiomyocytes; anti-LOX-1 monoclonal antibody treatment; infarct size quantification","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — in vivo antibody blockade with defined phenotypic readout (infarct size); single lab, single model","pmids":["12507499"],"is_preprint":false},{"year":2018,"finding":"miR-98 directly targets LOX-1 (confirmed by luciferase reporter assay on LOX-1 3'-UTR); miR-98 enhancement decreases LOX-1 expression and inhibits foam cell formation and lipid accumulation in macrophages; antagomiR-98 increases LOX-1 and promotes foam cell formation in ApoE-/- mice.","method":"Luciferase reporter assay confirming direct miR-98 targeting of LOX-1 3'-UTR; miR-98 mimics/inhibitors in mouse peritoneal macrophages; agomiR/antagomiR-98 in ApoE-/- mice on high-fat diet; LOX-1 expression and foam cell/lipid accumulation quantification","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase assay validates direct targeting; in vitro and in vivo models; single lab","pmids":["29549823"],"is_preprint":false},{"year":2015,"finding":"Membrane cholesterol depletion by MβCD or statins triggers LOX-1 shedding: cholesterol depletion promotes release of LOX-1 in exosomes as full-length transmembrane isoform and as a truncated soluble ectodomain fragment (sLOX-1) generated by a secreted metalloproteinase; long-term statin treatment enhances sLOX-1 proteolytic shedding.","method":"Cholesterol modulation with MβCD and statins in LOX-1-expressing cells and EA.hy926 endothelial cells; exosome isolation; western blot for full-length and truncated sLOX-1 forms; metalloproteinase activity experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — biochemical characterization of shedding products; multiple cell systems; mechanism linked to cholesterol and metalloproteinase activity; single lab","pmids":["26495844"],"is_preprint":false}],"current_model":"LOX (lysyl oxidase) is a secreted, copper-dependent amine oxidase that catalyzes the covalent cross-linking of collagen and elastin in the extracellular matrix via a quinone cofactor mechanism; its propeptide domain (LOX-PP) has separate tumor suppressor activity; intracellularly, LOX can enter the nucleus and transactivate gene promoters (e.g., SNAI2); it is regulated post-translationally by ubiquitination (via HRD1) and transcriptionally by NF-κB, OCT-1, AP-1, and miRNAs (let-7g, miR-98, miR-30a); disease-causing catalytic domain mutations reduce enzymatic activity and cause thoracic aortic aneurysms, while hypoxia-induced LOX promotes ECM stiffening, chemoresistance (via ITGA5/FN1/FAK-Src signaling), and mechanosensitive Piezo1 activation leading to ferroptosis. LOX-1 (OLR1), a distinct protein encoded by OLR1, is the main endothelial scavenger receptor for oxidized LDL that recognizes ox-LDL, phosphatidylserine, and activated platelets via a C-type lectin-like domain in a Ca2+-dependent manner; its atherogenic signaling is regulated by ADAM10-mediated ectodomain shedding and SPPL2a/b intramembrane proteolysis of the resulting NTFs, which otherwise activate MAP kinases ligand-independently."},"narrative":{"mechanistic_narrative":"The LOX symbol in this corpus resolves to two distinct proteins whose findings must be read separately: lysyl oxidase (LOX) and the oxidized-LDL scavenger receptor LOX-1 (OLR1). Lysyl oxidase is a copper-dependent amine oxidase that catalyzes covalent cross-linking of collagen and elastin in the extracellular matrix through a quinone cofactor mechanism, with its activity depending on a conserved copper-binding site and lysyl/tyrosyl residues, while its N-terminal propeptide constitutes a functionally separable regulatory module [PMID:12686136]. Catalytic-domain mutations (p.Ser280Arg, p.Ser348Arg) lower enzymatic activity, and LOX haploinsufficiency predisposes to thoracic aortic aneurysms and dissections, establishing LOX as a causal determinant of aortic structural integrity [PMID:26838787]. The propeptide (LOX-PP) carries a separable tumor-suppressor activity that opposes invasion, an activity abolished by the Arg158Gln variant [PMID:19654310]. Beyond ECM cross-linking, LOX is induced by hypoxia and HIF2A to drive fibrotic remodeling and chemoresistance, assembling fibronectin and signaling through ITGA5/FN1/FAK-Src [PMID:32415208, PMID:30388216], and its stiffening of the matrix activates mechanosensitive Piezo1 to trigger GPX4-dependent ferroptosis [PMID:39260063]. LOX also acts intracellularly and in the nucleus, transactivating the SNAI2 promoter to drive EMT [PMID:27029493, PMID:25790191], and influences osteoblast differentiation and ROS-mediated RANKL induction in bone [PMID:27606829, PMID:19458888]. LOX expression is controlled by inflammatory and miRNA inputs including Th17/IL-17-ERK-AP-1 versus Treg/IL-10-STAT3 signaling and direct repression by miR-30a [PMID:25488748, PMID:32649012]. Separately, LOX-1 (OLR1) is a Ca2+-dependent C-type lectin-like scavenger receptor that recognizes oxidized LDL, phosphatidylserine, and activated platelets [PMID:16146427, PMID:11263985], drives endothelial and macrophage atherogenic signaling via MAP kinase activation, NLRP3 inflammasome activation, and foam-cell formation [PMID:24776598, PMID:11735125], and is regulated by ADAM10/SPPL2-mediated proteolysis, HRD1-dependent ubiquitination, and let-7g/miR-98 [PMID:30819724, PMID:32308114, PMID:22135361, PMID:29549823].","teleology":[{"year":2000,"claim":"Established that LOX-1 (OLR1) scavenger receptor expression is differentially controlled relative to other modified-LDL receptors, framing it as a regulated determinant of macrophage lipid uptake.","evidence":"TGF-β1 treatment of THP-1 and primary human monocytes, RT-PCR and flow cytometry comparing CD36, SR-A and LOX-1","pmids":["10749696"],"confidence":"Medium","gaps":["Does not establish functional consequence for atherogenesis in vivo","Mechanism of differential transcriptional control not defined"]},{"year":2001,"claim":"Linked LOX-1 activation to a definable signaling output, placing ox-LDL→LOX-1→MAP kinase→eNOS suppression as an endothelial dysfunction axis and identifying platelet-borne LOX-1 as activation-dependent.","evidence":"Human coronary endothelial cells ± statins with eNOS/MAPK readouts; platelet RT-PCR, flow cytometry, and antibody blocking of ox-LDL binding","pmids":["11735125","11263985"],"confidence":"Medium","gaps":["Single cell type for endothelial signaling","Direct receptor-effector coupling not reconstituted"]},{"year":2003,"claim":"Defined the enzymatic and domain architecture of lysyl oxidase and showed transcriptional and ischemic induction of LOX-1, distinguishing the two proteins' biology.","evidence":"Domain/sequence analysis and BMP-1 processing for LOX; EMSA of NF-κB on LOX-1 promoter under high glucose; rat ischemia-reperfusion with anti-LOX-1 antibody","pmids":["12686136","12829655","12507499"],"confidence":"Medium","gaps":["LOX copper/quinone mechanism not reconstituted by full mutagenesis","LOX-1 cardiomyocyte mechanism limited to single model"]},{"year":2009,"claim":"Separated the LOX propeptide tumor-suppressor function from catalytic activity and revealed an intracellular role for LOX in osteoblast differentiation beyond ECM cross-linking.","evidence":"Arg158Gln LOX-PP variant in xenograft and invasion assays; Lox(-/-) primary calvarial osteoblasts with differentiation and DNA-synthesis readouts","pmids":["19654310","19458888"],"confidence":"High","gaps":["Molecular target of LOX-PP tumor suppression not identified","Mechanism of intracellular LOX action in osteoblasts undefined"]},{"year":2011,"claim":"Identified post-transcriptional control of LOX-1 by let-7g and its upstream OCT-1/PKC circuit, showing how ox-LDL feeds forward to sustain receptor expression.","evidence":"3'-UTR luciferase reporter, OCT-1 ChIP and promoter assay, let-7g mimics/inhibitors with Ca2+/PKC inhibitors","pmids":["22135361"],"confidence":"High","gaps":["In vivo relevance of the let-7g/OCT-1 loop not tested","Single regulatory cell context"]},{"year":2014,"claim":"Expanded the mechanistic reach of both proteins: LOX-1 to macrophage ROS→mtDNA damage→autophagy→NLRP3 inflammasome inflammation, and LOX to ROS-driven RANKL induction, nuclear localization in glioblastoma invasion, and miR-30a repression.","evidence":"LOX-1 siRNA/antibody with DNase II knockdown and NLRP3 assays; RANKL/RANK KO osteoclastogenesis; BAPN/siRNA in glioblastoma with localization IHC; miR-30a mimics in thyroid cancer models","pmids":["24776598","27606829","25790191","25488748"],"confidence":"High","gaps":["Nuclear import mechanism of LOX not defined","Direct LOX nuclear DNA targets in glioblastoma not mapped"]},{"year":2015,"claim":"Resolved how LOX-1 ligand binding is structurally constrained and reciprocally coupled to PCSK9, and characterized cholesterol-dependent shedding of soluble LOX-1.","evidence":"Statin docking/MD and dimer-stabilization westerns on the CTLD; reciprocal siRNA and KO mouse studies of LOX-1/PCSK9 with mtROS modulation; MβCD/statin shedding and exosome isolation experiments","pmids":["25950192","26092101","26495844"],"confidence":"Medium","gaps":["Crystallographic confirmation of statin binding absent","Identity of the shedding metalloproteinase not defined here"]},{"year":2016,"claim":"Established LOX as a disease-causing aortic gene through catalytic-loss mutations and as a nuclear transactivator of SNAI2 driving EMT.","evidence":"Exome sequencing, family segregation, and enzymatic assays of LOX mutants; ChIP and promoter luciferase of LOX on SNAI2 with in vivo thyroid metastasis model","pmids":["26838787","27029493"],"confidence":"High","gaps":["How nuclear LOX is targeted to specific promoters unknown","Relationship between secreted enzymatic LOX and nuclear LOX pool unresolved"]},{"year":2018,"claim":"Confirmed direct miR-98 targeting of LOX-1 as a brake on foam-cell formation in atherosclerosis.","evidence":"3'-UTR luciferase reporter, miR-98 mimics/inhibitors in macrophages, agomiR/antagomiR-98 in ApoE-/- mice","pmids":["29549823"],"confidence":"Medium","gaps":["Single miRNA among broader regulatory network","Tissue-specific delivery not addressed"]},{"year":2019,"claim":"Defined the proteolytic life cycle of LOX-1 controlling its atherogenic signaling, and placed HIF2A as the specific hypoxic driver of LOX-dependent fibrosis.","evidence":"ADAM10/SPPL2a/b substrate identification, TMD self-association, MAP kinase assays, SPPL2-deficient atherosclerosis mice; HIF2A shRNA/overexpression/inhibitor in orbital fibroblast organoids","pmids":["30819724","30388216"],"confidence":"High","gaps":["Physiological trigger of ligand-independent NTF signaling in vivo incompletely defined","HIF1A-vs-HIF2A selectivity mechanism for LOX not resolved"]},{"year":2020,"claim":"Connected LOX-1 turnover to E3 ligase control and tied LOX induction to ECM-driven chemoresistance and immune-cell signaling.","evidence":"HRD1-LOX-1 Co-IP, ubiquitination and KLF2 regulation in endothelium; LOX knockdown across organoids/xenografts/PDX with ITGA5/FN1/FAK-Src epistasis; Th17/Treg co-culture with pathway inhibitors and HF rat model","pmids":["32308114","32415208","32649012"],"confidence":"High","gaps":["HRD1 ubiquitination sites on LOX-1 not mapped","In vivo durability of LOX-targeted chemosensitization not established"]},{"year":2024,"claim":"Linked LOX-driven matrix stiffening to mechanotransduction, showing it activates Piezo1 to induce GPX4-dependent ferroptosis in hypoxic-ischemic brain injury.","evidence":"ECM stiffness and LOX activity assays in HIBD models, Piezo1 analysis, pharmacological LOX/Piezo1 inhibition, GPX4 ferroptosis markers, behavioral testing","pmids":["39260063"],"confidence":"Medium","gaps":["Direct biophysical coupling of LOX cross-links to Piezo1 gating not measured","Single-lab pathway requiring orthogonal confirmation"]},{"year":null,"claim":"How the secreted enzymatic, propeptide tumor-suppressor, and nuclear-transactivator activities of lysyl oxidase are partitioned and coordinated within a single gene product remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking catalytic, propeptide, and nuclear functions","Mechanism of LOX nuclear import and promoter selection unknown","Quantitative relationship between extracellular cross-linking and intracellular signaling pools undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,2]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[9]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[9,13,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[1,0]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,19]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[9,13,8]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[19]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,1,3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,17,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[15,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[22,10]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4]}],"complexes":[],"partners":["ITGA5","FN1","HRD1","ADAM10","SPPL2A","PCSK9","SNAI2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28300","full_name":"Protein-lysine 6-oxidase","aliases":["Lysyl oxidase"],"length_aa":417,"mass_kda":46.9,"function":"Responsible for the post-translational oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin (PubMed:26838787). Regulator of Ras expression. May play a role in tumor suppression. Plays a role in the aortic wall architecture (By similarity)","subcellular_location":"Secreted; Secreted, extracellular space","url":"https://www.uniprot.org/uniprotkb/P28300/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LOX","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LOX","total_profiled":1310},"omim":[{"mim_id":"620908","title":"ARTERIAL TORTUOSITY-BONE FRAGILITY SYNDROME; ATBFS","url":"https://www.omim.org/entry/620908"},{"mim_id":"620849","title":"SPERMATOGENIC FAILURE 93; SPGF93","url":"https://www.omim.org/entry/620849"},{"mim_id":"619018","title":"MICRO RNA 30B; MIR30B","url":"https://www.omim.org/entry/619018"},{"mim_id":"618455","title":"HEPHAESTIN-LIKE PROTEIN 1; HEPHL1","url":"https://www.omim.org/entry/618455"},{"mim_id":"617168","title":"AORTIC ANEURYSM, FAMILIAL THORACIC 10; AAT10","url":"https://www.omim.org/entry/617168"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/LOX"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P28300","domains":[{"cath_id":"-","chopping":"214-280_295-414","consensus_level":"high","plddt":93.1181,"start":214,"end":414}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28300","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28300-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28300-F1-predicted_aligned_error_v6.png","plddt_mean":67.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LOX","jax_strain_url":"https://www.jax.org/strain/search?query=LOX"},"sequence":{"accession":"P28300","fasta_url":"https://rest.uniprot.org/uniprotkb/P28300.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28300/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28300"}},"corpus_meta":[{"pmid":"23935243","id":"PMC_23935243","title":"LOX-1, OxLDL, and atherosclerosis.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23935243","citation_count":603,"is_preprint":false},{"pmid":"9608509","id":"PMC_9608509","title":"Inducible gene targeting in mice using the Cre/lox system.","date":"1998","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/9608509","citation_count":549,"is_preprint":false},{"pmid":"15240889","id":"PMC_15240889","title":"Cre-lox-regulated conditional RNA interference from transgenes.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15240889","citation_count":518,"is_preprint":false},{"pmid":"32415208","id":"PMC_32415208","title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32415208","citation_count":294,"is_preprint":false},{"pmid":"29737246","id":"PMC_29737246","title":"Role of Ox-LDL and LOX-1 in Atherogenesis.","date":"2019","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29737246","citation_count":252,"is_preprint":false},{"pmid":"21947818","id":"PMC_21947818","title":"Oxidized LDL, LOX-1 and atherosclerosis.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21947818","citation_count":243,"is_preprint":false},{"pmid":"23124189","id":"PMC_23124189","title":"LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.","date":"2012","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/23124189","citation_count":242,"is_preprint":false},{"pmid":"32176358","id":"PMC_32176358","title":"Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.","date":"2020","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32176358","citation_count":226,"is_preprint":false},{"pmid":"12686136","id":"PMC_12686136","title":"Structural and functional diversity of lysyl oxidase and the LOX-like proteins.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12686136","citation_count":208,"is_preprint":false},{"pmid":"31336709","id":"PMC_31336709","title":"LOX-1: Regulation, Signaling and Its Role in Atherosclerosis.","date":"2019","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31336709","citation_count":205,"is_preprint":false},{"pmid":"26092101","id":"PMC_26092101","title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26092101","citation_count":205,"is_preprint":false},{"pmid":"29336844","id":"PMC_29336844","title":"Detecting and Avoiding Problems When Using the Cre-lox System.","date":"2018","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/29336844","citation_count":199,"is_preprint":false},{"pmid":"17142375","id":"PMC_17142375","title":"Cre-lox-based system for multiple gene deletions and selectable-marker removal in Lactobacillus plantarum.","date":"2006","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17142375","citation_count":188,"is_preprint":false},{"pmid":"31746997","id":"PMC_31746997","title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1.","date":"2020","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/31746997","citation_count":184,"is_preprint":false},{"pmid":"26838787","id":"PMC_26838787","title":"LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections.","date":"2016","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/26838787","citation_count":176,"is_preprint":false},{"pmid":"28571642","id":"PMC_28571642","title":"LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation.","date":"2017","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28571642","citation_count":143,"is_preprint":false},{"pmid":"11263985","id":"PMC_11263985","title":"Activation-dependent surface expression of LOX-1 in human platelets.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11263985","citation_count":132,"is_preprint":false},{"pmid":"17569213","id":"PMC_17569213","title":"Regulation of COX and LOX by curcumin.","date":"2007","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/17569213","citation_count":130,"is_preprint":false},{"pmid":"21805404","id":"PMC_21805404","title":"The discovery of LOX-1, its ligands and clinical significance.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21805404","citation_count":130,"is_preprint":false},{"pmid":"24776598","id":"PMC_24776598","title":"LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis.","date":"2014","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/24776598","citation_count":117,"is_preprint":false},{"pmid":"29462603","id":"PMC_29462603","title":"LOX-1 receptor: A potential link in atherosclerosis and cancer.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29462603","citation_count":112,"is_preprint":false},{"pmid":"32708046","id":"PMC_32708046","title":"Lysyl Oxidase (LOX): Functional Contributions to Signaling Pathways.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32708046","citation_count":107,"is_preprint":false},{"pmid":"22661479","id":"PMC_22661479","title":"Variation in the lysyl oxidase (LOX) gene is associated with keratoconus in family-based and case-control studies.","date":"2012","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/22661479","citation_count":105,"is_preprint":false},{"pmid":"19801851","id":"PMC_19801851","title":"Lox-1: the multifunctional receptor underlying cardiovascular dysfunction.","date":"2009","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/19801851","citation_count":101,"is_preprint":false},{"pmid":"11735125","id":"PMC_11735125","title":"Inhibition of LOX-1 by statins may relate to upregulation of eNOS.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11735125","citation_count":95,"is_preprint":false},{"pmid":"22135361","id":"PMC_22135361","title":"Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22135361","citation_count":92,"is_preprint":false},{"pmid":"12829655","id":"PMC_12829655","title":"Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12829655","citation_count":91,"is_preprint":false},{"pmid":"33402733","id":"PMC_33402733","title":"LOX-1 and cancer: an indissoluble liaison.","date":"2021","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33402733","citation_count":89,"is_preprint":false},{"pmid":"33608525","id":"PMC_33608525","title":"Cas12a-assisted precise targeted cloning using in vivo Cre-lox recombination.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33608525","citation_count":89,"is_preprint":false},{"pmid":"17032731","id":"PMC_17032731","title":"Differential expression within the LOX gene family in ripening kiwifruit.","date":"2006","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/17032731","citation_count":87,"is_preprint":false},{"pmid":"24886290","id":"PMC_24886290","title":"LOX-1 and ROS, inseparable factors in the process of endothelial damage.","date":"2014","source":"Free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/24886290","citation_count":82,"is_preprint":false},{"pmid":"30388216","id":"PMC_30388216","title":"HIF2A-LOX Pathway Promotes Fibrotic Tissue Remodeling in Thyroid-Associated Orbitopathy.","date":"2019","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30388216","citation_count":81,"is_preprint":false},{"pmid":"25100742","id":"PMC_25100742","title":"Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25100742","citation_count":81,"is_preprint":false},{"pmid":"10749696","id":"PMC_10749696","title":"TGF-beta1 downregulates CD36 and scavenger receptor A but upregulates LOX-1 in human macrophages.","date":"2000","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10749696","citation_count":80,"is_preprint":false},{"pmid":"16146427","id":"PMC_16146427","title":"LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16146427","citation_count":79,"is_preprint":false},{"pmid":"30381837","id":"PMC_30381837","title":"Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives.","date":"2018","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30381837","citation_count":77,"is_preprint":false},{"pmid":"29209148","id":"PMC_29209148","title":"Human colorectal cancer progression correlates with LOX-induced ECM stiffening.","date":"2017","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29209148","citation_count":73,"is_preprint":false},{"pmid":"25488748","id":"PMC_25488748","title":"miR30a inhibits LOX expression and anaplastic thyroid cancer progression.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25488748","citation_count":71,"is_preprint":false},{"pmid":"31130685","id":"PMC_31130685","title":"Interplay Between LOX Enzymes and Integrins in the Tumor Microenvironment.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31130685","citation_count":62,"is_preprint":false},{"pmid":"27160316","id":"PMC_27160316","title":"LOX-1-Mediated Effects on Vascular Cells in Atherosclerosis.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27160316","citation_count":59,"is_preprint":false},{"pmid":"27029493","id":"PMC_27029493","title":"Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27029493","citation_count":58,"is_preprint":false},{"pmid":"19654310","id":"PMC_19654310","title":"A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19654310","citation_count":57,"is_preprint":false},{"pmid":"19458888","id":"PMC_19458888","title":"Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype.","date":"2009","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/19458888","citation_count":53,"is_preprint":false},{"pmid":"21084571","id":"PMC_21084571","title":"Good planning and serendipity: exploiting the Cre/Lox system in the testis.","date":"2010","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21084571","citation_count":53,"is_preprint":false},{"pmid":"31070916","id":"PMC_31070916","title":"Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31070916","citation_count":52,"is_preprint":false},{"pmid":"12820424","id":"PMC_12820424","title":"Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas.","date":"2003","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12820424","citation_count":50,"is_preprint":false},{"pmid":"10865829","id":"PMC_10865829","title":"Oxidized-LDL and atherosclerosis. Role of LOX-1.","date":"2000","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10865829","citation_count":47,"is_preprint":false},{"pmid":"22777292","id":"PMC_22777292","title":"LOX-1: a multiligand receptor at the crossroads of response to danger signals.","date":"2012","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/22777292","citation_count":47,"is_preprint":false},{"pmid":"26907636","id":"PMC_26907636","title":"Roles of LOX-1 in microvascular dysfunction.","date":"2016","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26907636","citation_count":47,"is_preprint":false},{"pmid":"11016533","id":"PMC_11016533","title":"Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats.","date":"2000","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/11016533","citation_count":47,"is_preprint":false},{"pmid":"34976220","id":"PMC_34976220","title":"Dysregulation of interaction between LOXhigh fibroblast and smooth muscle cells contributes to the pathogenesis of aortic dissection.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34976220","citation_count":46,"is_preprint":false},{"pmid":"30639239","id":"PMC_30639239","title":"LOX-1 and atherosclerotic-related diseases.","date":"2019","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30639239","citation_count":46,"is_preprint":false},{"pmid":"24959993","id":"PMC_24959993","title":"LOX-1, oxidant stress, mtDNA damage, autophagy, and immune response in atherosclerosis.","date":"2014","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24959993","citation_count":46,"is_preprint":false},{"pmid":"24874786","id":"PMC_24874786","title":"FLP/FRT and Cre/lox recombination technology in C. elegans.","date":"2014","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/24874786","citation_count":46,"is_preprint":false},{"pmid":"32649012","id":"PMC_32649012","title":"Th17/Treg imbalance modulates rat myocardial fibrosis and heart failure by regulating LOX expression.","date":"2020","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32649012","citation_count":46,"is_preprint":false},{"pmid":"25790191","id":"PMC_25790191","title":"LOX expression and functional analysis in astrocytomas and impact of IDH1 mutation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25790191","citation_count":45,"is_preprint":false},{"pmid":"11230317","id":"PMC_11230317","title":"Identification of peptides that target the endothelial cell-specific LOX-1 receptor.","date":"2001","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11230317","citation_count":45,"is_preprint":false},{"pmid":"27606829","id":"PMC_27606829","title":"LOX Fails to Substitute for RANKL in Osteoclastogenesis.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/27606829","citation_count":44,"is_preprint":false},{"pmid":"25950192","id":"PMC_25950192","title":"Molecular mechanism of statin-mediated LOX-1 inhibition.","date":"2015","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25950192","citation_count":43,"is_preprint":false},{"pmid":"27694040","id":"PMC_27694040","title":"LOX-1 and TLR4 affect each other and regulate the generation of ROS in A. fumigatus keratitis.","date":"2016","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27694040","citation_count":43,"is_preprint":false},{"pmid":"36706988","id":"PMC_36706988","title":"Single-cell analysis reveals lysyl oxidase (Lox)+ fibroblast subset involved in cardiac fibrosis of diabetic mice.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/36706988","citation_count":42,"is_preprint":false},{"pmid":"30098867","id":"PMC_30098867","title":"Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.","date":"2018","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/30098867","citation_count":42,"is_preprint":false},{"pmid":"21861069","id":"PMC_21861069","title":"LOX-1 and angiotensin receptors, and their interplay.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21861069","citation_count":41,"is_preprint":false},{"pmid":"12507499","id":"PMC_12507499","title":"LOX-1 pathway affects the extent of myocardial ischemia-reperfusion injury.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12507499","citation_count":41,"is_preprint":false},{"pmid":"25463747","id":"PMC_25463747","title":"LOX-1 in atherosclerotic disease.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25463747","citation_count":40,"is_preprint":false},{"pmid":"28084571","id":"PMC_28084571","title":"Xanthine Oxidase Induces Foam Cell Formation through LOX-1 and NLRP3 Activation.","date":"2017","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28084571","citation_count":40,"is_preprint":false},{"pmid":"29549823","id":"PMC_29549823","title":"MicroRNA-98 regulates foam cell formation and lipid accumulation through repression of LOX-1.","date":"2018","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/29549823","citation_count":40,"is_preprint":false},{"pmid":"30712446","id":"PMC_30712446","title":"LOX and ACSL5 as potential relapse markers for pancreatic cancer patients.","date":"2019","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30712446","citation_count":36,"is_preprint":false},{"pmid":"28146073","id":"PMC_28146073","title":"LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28146073","citation_count":35,"is_preprint":false},{"pmid":"33388012","id":"PMC_33388012","title":"Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer.","date":"2021","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/33388012","citation_count":35,"is_preprint":false},{"pmid":"31350594","id":"PMC_31350594","title":"Upregulated LOX-1 Receptor: Key Player of the Pathogenesis of Atherosclerosis.","date":"2019","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/31350594","citation_count":34,"is_preprint":false},{"pmid":"30819724","id":"PMC_30819724","title":"Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30819724","citation_count":34,"is_preprint":false},{"pmid":"24000272","id":"PMC_24000272","title":"Oxidized LDL and LOX-1 in experimental sepsis.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24000272","citation_count":32,"is_preprint":false},{"pmid":"21796333","id":"PMC_21796333","title":"LOX-1 transcription.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21796333","citation_count":31,"is_preprint":false},{"pmid":"21881850","id":"PMC_21881850","title":"LOX-1 and obesity.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21881850","citation_count":30,"is_preprint":false},{"pmid":"22454776","id":"PMC_22454776","title":"The LOX-1 Scavenger Receptor and Its Implications in the Treatment of Vascular Disease.","date":"2012","source":"Cardiology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/22454776","citation_count":30,"is_preprint":false},{"pmid":"17484769","id":"PMC_17484769","title":"Expression of 5-lipoxygenase (5-LOX) in T lymphocytes.","date":"2007","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17484769","citation_count":28,"is_preprint":false},{"pmid":"30718451","id":"PMC_30718451","title":"Pro-oncogenic action of LOX-1 and its splice variant LOX-1Δ4 in breast cancer phenotypes.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30718451","citation_count":27,"is_preprint":false},{"pmid":"32308114","id":"PMC_32308114","title":"HRD1 prevents atherosclerosis-mediated endothelial cell apoptosis by promoting LOX-1 degradation.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32308114","citation_count":27,"is_preprint":false},{"pmid":"31921422","id":"PMC_31921422","title":"LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.","date":"2020","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/31921422","citation_count":27,"is_preprint":false},{"pmid":"24756769","id":"PMC_24756769","title":"Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.","date":"2014","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24756769","citation_count":27,"is_preprint":false},{"pmid":"21912849","id":"PMC_21912849","title":"Novel concepts in the genesis of hypertension: role of LOX-1.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21912849","citation_count":26,"is_preprint":false},{"pmid":"21968594","id":"PMC_21968594","title":"Angiogenesis is a link between atherosclerosis and tumorigenesis: role of LOX-1.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21968594","citation_count":24,"is_preprint":false},{"pmid":"29859535","id":"PMC_29859535","title":"Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29859535","citation_count":24,"is_preprint":false},{"pmid":"26495844","id":"PMC_26495844","title":"Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26495844","citation_count":24,"is_preprint":false},{"pmid":"35713402","id":"PMC_35713402","title":"Cre/lox regulated conditional rescue and inactivation with zebrafish UFlip alleles generated by CRISPR-Cas9 targeted integration.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35713402","citation_count":23,"is_preprint":false},{"pmid":"23073021","id":"PMC_23073021","title":"Plant 9-lox oxylipin metabolism in response to arbuscular mycorrhiza.","date":"2012","source":"Plant signaling & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/23073021","citation_count":23,"is_preprint":false},{"pmid":"34118114","id":"PMC_34118114","title":"Effects of Apigenin on the Expression of LOX-1, Bcl-2, and Bax in Hyperlipidemia Rats.","date":"2021","source":"Chemistry & biodiversity","url":"https://pubmed.ncbi.nlm.nih.gov/34118114","citation_count":22,"is_preprint":false},{"pmid":"32182251","id":"PMC_32182251","title":"LOX-1: A potential driver of cardiovascular risk in SLE patients.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32182251","citation_count":22,"is_preprint":false},{"pmid":"7840765","id":"PMC_7840765","title":"TKO'ed: lox, stock and barrel.","date":"1994","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7840765","citation_count":22,"is_preprint":false},{"pmid":"35356112","id":"PMC_35356112","title":"Identification of the LOX Gene Family in Peanut and Functional Characterization of AhLOX29 in Drought Tolerance.","date":"2022","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/35356112","citation_count":21,"is_preprint":false},{"pmid":"18561999","id":"PMC_18561999","title":"5-LOX, 12-LOX and 15-LOX in immature forms of human leukemic blasts.","date":"2008","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/18561999","citation_count":21,"is_preprint":false},{"pmid":"24391998","id":"PMC_24391998","title":"TAILOR: transgene activation and inactivation using lox and rox in zebrafish.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24391998","citation_count":21,"is_preprint":false},{"pmid":"34439368","id":"PMC_34439368","title":"Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34439368","citation_count":21,"is_preprint":false},{"pmid":"38791315","id":"PMC_38791315","title":"LOX-1 in Cardiovascular Disease: A Comprehensive Molecular and Clinical Review.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38791315","citation_count":20,"is_preprint":false},{"pmid":"21904818","id":"PMC_21904818","title":"LOX-1/LOXIN: the yin/yang of atheroscleorosis.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21904818","citation_count":20,"is_preprint":false},{"pmid":"35168324","id":"PMC_35168324","title":"Cre/lox-Mediated Chromosomal Integration of Biosynthetic Gene Clusters for Heterologous Expression in Aspergillus nidulans.","date":"2022","source":"ACS synthetic biology","url":"https://pubmed.ncbi.nlm.nih.gov/35168324","citation_count":20,"is_preprint":false},{"pmid":"29661738","id":"PMC_29661738","title":"Overexpression of Lox in triple-negative breast cancer.","date":"2018","source":"Annals of diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29661738","citation_count":20,"is_preprint":false},{"pmid":"39260063","id":"PMC_39260063","title":"LOX-mediated ECM mechanical stress induces Piezo1 activation in hypoxic-ischemic brain damage and identification of novel inhibitor of LOX.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/39260063","citation_count":19,"is_preprint":false},{"pmid":"16969095","id":"PMC_16969095","title":"Lysyl oxidase (LOX) and hypoxia-induced metastases.","date":"2006","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16969095","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47546,"output_tokens":7228,"usd":0.125529,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16530,"output_tokens":4929,"usd":0.102938,"stage2_stop_reason":"end_turn"},"total_usd":0.228467,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"LOX catalytic domain mutations (p.Ser280Arg and p.Ser348Arg) result in significantly lower lysyl oxidase enzymatic activity compared to wild-type protein, and LOX haploinsufficiency predisposes to thoracic aortic aneurysms and dissections, placing LOX as a causal component of aortic structural integrity via its collagen/elastin cross-linking activity.\",\n      \"method\": \"Exome sequencing to identify variants, functional assay of lysyl oxidase enzymatic activity for mutant vs. wild-type protein, segregation analysis in families\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct enzymatic activity assay of disease-causing mutants with multiple independent families and genetic segregation evidence\",\n      \"pmids\": [\"26838787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LOX, induced by hypoxia, promotes chemoresistance in triple-negative breast cancer by cross-linking collagen and assembling fibronectin in the ECM; LOX inhibition reduces collagen cross-linking and fibronectin assembly, decreases drug penetration barrier, downregulates ITGA5/FN1 expression, and inhibits FAK/Src signaling, leading to apoptosis and chemosensitization.\",\n      \"method\": \"LOX inhibition/knockdown in 3D cell lines, tumor organoids, xenografts, syngeneic tumors, and PDX models; RNA-sequencing; miR-142-3p re-expression targeting HIF1A/LOX/ITGA5 axis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal models (organoids, xenografts, PDX), mechanistic pathway placed with epistasis (LOX→ITGA5/FN1→FAK/Src), replicated across systems\",\n      \"pmids\": [\"32415208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LOX (lysyl oxidase) is a copper-dependent amine oxidase that requires a conserved copper binding site, lysyl and tyrosyl residues contributing to quinone cofactor formation, and a cytokine receptor-like domain for function; the N-terminal propeptide domain confers unique regulatory properties distinct from the catalytic C-terminal domain.\",\n      \"method\": \"Structural/domain analysis, comparative expression and sequence analysis across LOX family members including Drosophila orthologs; BMP-1 processing assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — domain mapping and comparative analysis without full mutagenesis reconstitution; consistent across family members\",\n      \"pmids\": [\"12686136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HIF2A (but not HIF1A) directly induces LOX expression to promote collagen cross-linking and fibrotic ECM deposition in orbital fibroblasts; inhibition of HIF2A or LOX (by shRNA or small molecule antagonists) ameliorated fibrosis in 3D organoids, and constitutively active HIF2A was sufficient to initiate LOX-dependent fibrotic remodeling.\",\n      \"method\": \"shRNA knockdown, small molecule inhibitor experiments, HIF2A overexpression in 3D organoid cultures of human orbital fibroblasts, validated in human TAO tissues\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (HIF2A→LOX→fibrosis), multiple orthogonal approaches (shRNA, overexpression, pharmacological inhibition) in a single lab\",\n      \"pmids\": [\"30388216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LOX transcriptionally activates the SNAI2 promoter (demonstrated by chromatin immunoprecipitation and promoter luciferase assays), and the LOX/SNAI2 axis regulates TIMP4 secretion, thereby mediating epithelial-to-mesenchymal transition and cancer progression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter luciferase assays, siRNA knockdown, in vivo metastatic mouse model of thyroid cancer, protein arrays for MMPs/TIMPs, IHC on patient samples\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct ChIP and promoter assay establish LOX binding to SNAI2 promoter; multiple orthogonal methods (ChIP, luciferase, in vivo model) in single lab\",\n      \"pmids\": [\"27029493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A SNP (G473A; Arg158Gln) in the LOX propeptide domain (LOX-PP) profoundly impairs the ability of LOX-PP to inhibit tumor invasion and xenograft tumor formation, identifying the propeptide as the tumor suppressor domain of LOX and demonstrating that the Gln variant cannot oppose LOX enzymatic activity-promoted invasion.\",\n      \"method\": \"Xenograft tumor formation assays, invasion assays comparing Arg158 vs Gln158 LOX-PP variants, comparison of LOX-PP vs. LOX enzymatic effects on invasive phenotype\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional mutagenesis (Arg→Gln substitution) with in vivo xenograft assay and in vitro invasion assay establishing LOX-PP as tumor suppressor domain\",\n      \"pmids\": [\"19654310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LOX promotes RANKL expression in bone marrow stromal cells via production of reactive oxygen species (ROS), which indirectly stimulates osteoclastogenesis; however, LOX cannot substitute for RANKL and does not induce osteoclast differentiation in RANKL-deficient or RANK-deficient cells.\",\n      \"method\": \"In vitro osteoclastogenesis assays with wild-type, RANKL-KO, and RANK-KO cells; LOX injection in RANKL-deficient mice; TRAP staining; resorption pit assays\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis using KO cells and animals, multiple cell types; clearly defines LOX mechanism (ROS→RANKL induction) and its limits (cannot replace RANKL)\",\n      \"pmids\": [\"27606829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LOX gene deficiency in osteoblasts reduces DNA synthesis, impairs mineral nodule formation, and markedly decreases osteoblastic differentiation markers (type I collagen, bone sialoprotein, Runx2/Cbfa1), establishing a role for LOX in osteoblast phenotype beyond extracellular collagen cross-linking.\",\n      \"method\": \"Primary calvarial osteoblasts from Lox(-/-) knockout mice; DNA synthesis assays; annexin-V apoptosis assays; RT-PCR and immunostaining for differentiation markers\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — LOX KO primary cells with multiple phenotypic readouts; clean loss-of-function with defined cellular phenotype\",\n      \"pmids\": [\"19458888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LOX intramembrane proteolysis by SPPL2a/b controls atherogenic LOX-1 (OLR1) signaling: ADAM10 sheds the LOX-1 ectodomain generating N-terminal fragments (NTFs) that self-associate via their transmembrane domains and activate MAP kinases in a ligand-independent manner, upregulating ICAM-1 and CTGF; SPPL2a/b deficiency causes NTF accumulation, enlarging atherosclerotic plaques.\",\n      \"method\": \"Identification of ADAM10 shedding and SPPL2a/b substrates by biochemical assays; MAP kinase activation assays; SPPL2a/b-deficient mouse atherosclerosis models; transmembrane domain self-association experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic dissection of LOX-1 proteolytic processing with KO mice, substrate identification, and defined signaling consequences; multiple orthogonal methods\",\n      \"pmids\": [\"30819724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LOX-1 (OLR1) recognizes phosphatidylserine (PS) in a Ca2+-dependent manner; recombinant glycosylated LOX-1 binds PS but not other phospholipids, and this recognition is maximal with millimolar Ca2+ but not Mg2+; LOX-1-mediated recognition of PS-containing apoptotic bodies is blocked by bivalent-cation chelation or LOX-1-blocking antibodies.\",\n      \"method\": \"In vitro binding assays with recombinant glycosylated LOX-1; cell-based PS recognition assays; Ca2+/Mg2+ substitution; blocking antibodies; PS-containing liposome competition\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro binding with recombinant protein, Ca2+ specificity demonstrated by ion substitution, validated in cells with blocking antibodies\",\n      \"pmids\": [\"16146427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HRD1 (E3 ubiquitin ligase) directly interacts with LOX-1 and promotes its ubiquitination and proteasomal degradation; KLF2 transcription factor positively regulates HRD1 expression, and decreased HRD1 leads to LOX-1 accumulation and endothelial apoptosis; LOX-1 deletion attenuated apoptosis caused by HRD1 downregulation.\",\n      \"method\": \"Co-immunoprecipitation (HRD1-LOX-1 interaction), ubiquitination assay, proteasome inhibitor experiments, KLF2 promoter binding assay, HRD1 overexpression/knockdown in endothelial cells, LOX-1 deletion epistasis\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing interaction, ubiquitination assay confirming PTM (ubiquitination), epistasis (LOX-1 KD rescues HRD1-KD phenotype), single lab\",\n      \"pmids\": [\"32308114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Statins directly interact with the C-type lectin-like (CTLD) recognition domain of LOX-1, filling the hydrophobic tunnel and stabilizing the LOX-1 dimer assembly; this mechanism underlies statin-mediated inhibition of ox-LDL binding to LOX-1 independent of cholesterol lowering.\",\n      \"method\": \"Cell-based fluorescent ox-LDL displacement binding assay, molecular docking simulations, molecular dynamics simulation, electrophoretic separation and western blot for dimer stabilization\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — cell-based binding assay and structural modeling with biochemical validation of dimer stabilization; computational plus experimental, single lab\",\n      \"pmids\": [\"25950192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"High glucose induces LOX-1 expression in human aortic endothelial cells at the transcriptional level through increased oxidant stress and activation of NF-κB, PKC, and MAPK signaling; LOX-1 upregulation mediates high glucose-induced monocyte adhesion to endothelium.\",\n      \"method\": \"RT-PCR, protein expression, EMSA (NF-κB binding to LOX-1 promoter), pharmacological inhibitors of NF-κB/PKC/MAPK, anti-LOX-1 antibody blocking monocyte adhesion\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA demonstrates transcription factor binding to LOX-1 promoter; multiple pathway inhibitors with functional readout (monocyte adhesion), single lab\",\n      \"pmids\": [\"12829655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"LOX-1 is expressed in human platelets (mRNA and protein) and is stored intracellularly, becoming surface-exposed in an activation-dependent manner; activated platelet LOX-1 mediates ox-LDL binding, and accumulates at thrombus sites in atherosclerotic plaques.\",\n      \"method\": \"RT-PCR, protein detection, flow cytometry on activated vs. resting platelets, anti-LOX-1 antibody blocking of ox-LDL binding, immunohistochemistry of atherosclerotic plaque\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — flow cytometry documenting activation-dependent surface translocation; antibody blocking of function; consistent across cell lines and primary platelets\",\n      \"pmids\": [\"11263985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"microRNA let-7g negatively regulates LOX-1 expression via a binding site in the 3'-UTR of LOX-1 mRNA; ox-LDL reduces let-7g expression through a Ca2+-activated PKC pathway; OCT-1 represses let-7g promoter activity; let-7g overexpression inhibits ox-LDL-induced LOX-1/OCT-1 expression and cell proliferation and migration.\",\n      \"method\": \"3'-UTR luciferase reporter assay confirming let-7g binding site, promoter assay for OCT-1 binding to let-7g promoter, chromatin immunoprecipitation (ChIP), transfection of let-7g mimics/inhibitors, Ca2+/PKC inhibitor studies\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — luciferase reporter establishes direct miRNA binding to LOX-1 3'-UTR; ChIP validates OCT-1 binding; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"22135361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LOX-1 activation in macrophages drives ROS generation, mitochondrial DNA damage, and autophagy, which together activate the NLRP3 inflammasome; LOX-1 inhibition (antibody or siRNA) suppresses ROS, autophagy, mtDNA damage, and NLRP3 activation; DNase II knockdown inhibits autophagy and NLRP3 inflammasome downstream of damaged mtDNA.\",\n      \"method\": \"LOX-1 siRNA/antibody inhibition in THP-1 macrophages and primary macrophages, ROS inhibitors, autophagy inducer/inhibitor, DNase II knockdown, NLRP3 inflammasome activation assays\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established with multiple genetic and pharmacological interventions; pathway defined (LOX-1→ROS→mtDNA damage→autophagy→NLRP3); replicated in primary and cell line models\",\n      \"pmids\": [\"24776598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LOX (lysyl oxidase) and PCSK9 positively regulate each other's expression in vascular cells; siRNA knockdown of PCSK9 reduces LOX-1 expression and function; LOX-1 knockdown reduces PCSK9 expression; LOX-1 KO mice express less PCSK9 and PCSK9-KO mice express less LOX-1; mitochondrial ROS initiates this mutual regulation, acting upstream of both.\",\n      \"method\": \"siRNA transfection (PCSK9 and LOX-1 knockdown), recombinant hPCSK9 treatment, LOX-1 cDNA overexpression, LOX-1 and PCSK9 KO mouse studies, mtROS induction/inhibition\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal siRNA knockdown, KO mouse models for both genes, and pharmacological epistasis with mtROS; multiple orthogonal approaches\",\n      \"pmids\": [\"26092101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Statins (simvastatin, atorvastatin) reduce ox-LDL-induced LOX-1 upregulation and simultaneously prevent LOX-1-mediated suppression of eNOS expression; LOX-1 activation by ox-LDL also activates MAP kinase, and statin attenuation of MAP kinase provides a mechanism for eNOS restoration.\",\n      \"method\": \"Human coronary artery endothelial cells treated with ox-LDL ± statins; LOX-1 and eNOS expression by western blot; MAP kinase activation assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — single lab, single cell type, dose-response data; places LOX-1→MAP kinase→eNOS in a signaling pathway but limited mechanistic depth\",\n      \"pmids\": [\"11735125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TGF-β1 differentially regulates scavenger receptors in human macrophages: it decreases CD36 and SR-A expression while upregulating LOX-1 mRNA, thereby altering the balance of modified LDL uptake and foam cell formation.\",\n      \"method\": \"RT-PCR and flow cytometry in THP-1 cells and primary human monocytes treated with TGF-β1; measurements of scavenger receptor expression and total ox-LDL uptake\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — RT-PCR and protein expression in both cell line and primary human cells; multiple scavenger receptors compared as controls\",\n      \"pmids\": [\"10749696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LOX inhibition (by BAPN) in glioblastoma cell lines reduces migration, invasion, and soft agar colony formation; LOX protein localizes to cytoplasm and nucleus, with nuclear localization being lower in IDH1-mutant glioblastoma.\",\n      \"method\": \"siRNA knockdown and BAPN pharmacological inhibition of LOX in U87MG and A172 glioblastoma cell lines; migration, invasion, and colony formation assays; immunohistochemistry for subcellular localization\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — functional assays (migration, invasion) with both genetic and pharmacological LOX inhibition; single lab, single cell type pair\",\n      \"pmids\": [\"25790191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR30a directly targets and represses LOX expression (identified as a direct target via miRNA target prediction validated experimentally); LOX inhibition decreases cellular invasion, migration, EMT marker levels, and metastatic capacity in thyroid cancer models in vitro and in vivo.\",\n      \"method\": \"miR30a mimic/inhibitor transfections, LOX expression analysis, in vitro invasion/migration assays, in vivo metastasis model; LOX identified as direct miR30a target\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — functional assays in vitro and in vivo; direct miRNA-LOX targeting established; single lab but in vivo validation included\",\n      \"pmids\": [\"25488748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Th17 cells promote LOX expression via the IL-17/ERK1/2-AP-1 signaling pathway, while Tregs inhibit LOX expression via the IL-10/JAK1-STAT3 pathway; LOX upregulation mediates increased collagen cross-linking and myocardial fibrosis in cardiac fibroblasts.\",\n      \"method\": \"Co-culture of cardiac fibroblasts with polarized Th17/Treg cells; BAPN LOX inhibitor; signaling pathway inhibitors; adoptive transfer in HF rat model; LOX expression and collagen deposition measurements\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models; specific signaling pathways identified for both Th17 and Treg regulation of LOX; single lab\",\n      \"pmids\": [\"32649012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LOX-mediated ECM cross-linking increases tissue stiffness, which activates mechanosensitive Piezo1 channels in neurons; Piezo1 activation induces ferroptosis in a GPX4-dependent manner in hypoxic-ischemic brain damage; pharmacological LOX inhibition with traumatic acid (identified as a novel LOX inhibitor) reduces neuronal ferroptosis and improves neurological outcomes.\",\n      \"method\": \"LOX activity measurement in HIBD models in vivo and in vitro, ECM stiffness assays, Piezo1 expression/activation analysis, LOX/Piezo1 pharmacological inhibition, LOX inhibitor (traumatic acid) enzymatic activity assay, ferroptosis markers (GPX4), behavioral testing\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway (LOX→ECM stiffness→Piezo1→ferroptosis) defined with pharmacological interventions at multiple steps; in vitro and in vivo; single lab\",\n      \"pmids\": [\"39260063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LOX-1 pathway activation in cardiomyocytes following ischemia-reperfusion (but not ischemia alone) contributes to myocardial infarction; anti-LOX-1 monoclonal antibody treatment reduced myocardial infarction size by ~50% in a rat coronary artery ligation/reperfusion model.\",\n      \"method\": \"Rat ischemia-reperfusion model; immunohistochemistry for LOX-1 induction in cardiomyocytes; anti-LOX-1 monoclonal antibody treatment; infarct size quantification\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — in vivo antibody blockade with defined phenotypic readout (infarct size); single lab, single model\",\n      \"pmids\": [\"12507499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-98 directly targets LOX-1 (confirmed by luciferase reporter assay on LOX-1 3'-UTR); miR-98 enhancement decreases LOX-1 expression and inhibits foam cell formation and lipid accumulation in macrophages; antagomiR-98 increases LOX-1 and promotes foam cell formation in ApoE-/- mice.\",\n      \"method\": \"Luciferase reporter assay confirming direct miR-98 targeting of LOX-1 3'-UTR; miR-98 mimics/inhibitors in mouse peritoneal macrophages; agomiR/antagomiR-98 in ApoE-/- mice on high-fat diet; LOX-1 expression and foam cell/lipid accumulation quantification\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase assay validates direct targeting; in vitro and in vivo models; single lab\",\n      \"pmids\": [\"29549823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Membrane cholesterol depletion by MβCD or statins triggers LOX-1 shedding: cholesterol depletion promotes release of LOX-1 in exosomes as full-length transmembrane isoform and as a truncated soluble ectodomain fragment (sLOX-1) generated by a secreted metalloproteinase; long-term statin treatment enhances sLOX-1 proteolytic shedding.\",\n      \"method\": \"Cholesterol modulation with MβCD and statins in LOX-1-expressing cells and EA.hy926 endothelial cells; exosome isolation; western blot for full-length and truncated sLOX-1 forms; metalloproteinase activity experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — biochemical characterization of shedding products; multiple cell systems; mechanism linked to cholesterol and metalloproteinase activity; single lab\",\n      \"pmids\": [\"26495844\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LOX (lysyl oxidase) is a secreted, copper-dependent amine oxidase that catalyzes the covalent cross-linking of collagen and elastin in the extracellular matrix via a quinone cofactor mechanism; its propeptide domain (LOX-PP) has separate tumor suppressor activity; intracellularly, LOX can enter the nucleus and transactivate gene promoters (e.g., SNAI2); it is regulated post-translationally by ubiquitination (via HRD1) and transcriptionally by NF-κB, OCT-1, AP-1, and miRNAs (let-7g, miR-98, miR-30a); disease-causing catalytic domain mutations reduce enzymatic activity and cause thoracic aortic aneurysms, while hypoxia-induced LOX promotes ECM stiffening, chemoresistance (via ITGA5/FN1/FAK-Src signaling), and mechanosensitive Piezo1 activation leading to ferroptosis. LOX-1 (OLR1), a distinct protein encoded by OLR1, is the main endothelial scavenger receptor for oxidized LDL that recognizes ox-LDL, phosphatidylserine, and activated platelets via a C-type lectin-like domain in a Ca2+-dependent manner; its atherogenic signaling is regulated by ADAM10-mediated ectodomain shedding and SPPL2a/b intramembrane proteolysis of the resulting NTFs, which otherwise activate MAP kinases ligand-independently.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"The LOX symbol in this corpus resolves to two distinct proteins whose findings must be read separately: lysyl oxidase (LOX) and the oxidized-LDL scavenger receptor LOX-1 (OLR1). Lysyl oxidase is a copper-dependent amine oxidase that catalyzes covalent cross-linking of collagen and elastin in the extracellular matrix through a quinone cofactor mechanism, with its activity depending on a conserved copper-binding site and lysyl/tyrosyl residues, while its N-terminal propeptide constitutes a functionally separable regulatory module [#2]. Catalytic-domain mutations (p.Ser280Arg, p.Ser348Arg) lower enzymatic activity, and LOX haploinsufficiency predisposes to thoracic aortic aneurysms and dissections, establishing LOX as a causal determinant of aortic structural integrity [#0]. The propeptide (LOX-PP) carries a separable tumor-suppressor activity that opposes invasion, an activity abolished by the Arg158Gln variant [#5]. Beyond ECM cross-linking, LOX is induced by hypoxia and HIF2A to drive fibrotic remodeling and chemoresistance, assembling fibronectin and signaling through ITGA5/FN1/FAK-Src [#1, #3], and its stiffening of the matrix activates mechanosensitive Piezo1 to trigger GPX4-dependent ferroptosis [#22]. LOX also acts intracellularly and in the nucleus, transactivating the SNAI2 promoter to drive EMT [#4, #19], and influences osteoblast differentiation and ROS-mediated RANKL induction in bone [#6, #7]. LOX expression is controlled by inflammatory and miRNA inputs including Th17/IL-17-ERK-AP-1 versus Treg/IL-10-STAT3 signaling and direct repression by miR-30a [#20, #21]. Separately, LOX-1 (OLR1) is a Ca2+-dependent C-type lectin-like scavenger receptor that recognizes oxidized LDL, phosphatidylserine, and activated platelets [#9, #13], drives endothelial and macrophage atherogenic signaling via MAP kinase activation, NLRP3 inflammasome activation, and foam-cell formation [#15, #17], and is regulated by ADAM10/SPPL2-mediated proteolysis, HRD1-dependent ubiquitination, and let-7g/miR-98 [#8, #10, #14, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that LOX-1 (OLR1) scavenger receptor expression is differentially controlled relative to other modified-LDL receptors, framing it as a regulated determinant of macrophage lipid uptake.\",\n      \"evidence\": \"TGF-\\u03b21 treatment of THP-1 and primary human monocytes, RT-PCR and flow cytometry comparing CD36, SR-A and LOX-1\",\n      \"pmids\": [\"10749696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish functional consequence for atherogenesis in vivo\", \"Mechanism of differential transcriptional control not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Linked LOX-1 activation to a definable signaling output, placing ox-LDL\\u2192LOX-1\\u2192MAP kinase\\u2192eNOS suppression as an endothelial dysfunction axis and identifying platelet-borne LOX-1 as activation-dependent.\",\n      \"evidence\": \"Human coronary endothelial cells \\u00b1 statins with eNOS/MAPK readouts; platelet RT-PCR, flow cytometry, and antibody blocking of ox-LDL binding\",\n      \"pmids\": [\"11735125\", \"11263985\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell type for endothelial signaling\", \"Direct receptor-effector coupling not reconstituted\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined the enzymatic and domain architecture of lysyl oxidase and showed transcriptional and ischemic induction of LOX-1, distinguishing the two proteins' biology.\",\n      \"evidence\": \"Domain/sequence analysis and BMP-1 processing for LOX; EMSA of NF-\\u03baB on LOX-1 promoter under high glucose; rat ischemia-reperfusion with anti-LOX-1 antibody\",\n      \"pmids\": [\"12686136\", \"12829655\", \"12507499\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LOX copper/quinone mechanism not reconstituted by full mutagenesis\", \"LOX-1 cardiomyocyte mechanism limited to single model\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Separated the LOX propeptide tumor-suppressor function from catalytic activity and revealed an intracellular role for LOX in osteoblast differentiation beyond ECM cross-linking.\",\n      \"evidence\": \"Arg158Gln LOX-PP variant in xenograft and invasion assays; Lox(-/-) primary calvarial osteoblasts with differentiation and DNA-synthesis readouts\",\n      \"pmids\": [\"19654310\", \"19458888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of LOX-PP tumor suppression not identified\", \"Mechanism of intracellular LOX action in osteoblasts undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified post-transcriptional control of LOX-1 by let-7g and its upstream OCT-1/PKC circuit, showing how ox-LDL feeds forward to sustain receptor expression.\",\n      \"evidence\": \"3'-UTR luciferase reporter, OCT-1 ChIP and promoter assay, let-7g mimics/inhibitors with Ca2+/PKC inhibitors\",\n      \"pmids\": [\"22135361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of the let-7g/OCT-1 loop not tested\", \"Single regulatory cell context\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Expanded the mechanistic reach of both proteins: LOX-1 to macrophage ROS\\u2192mtDNA damage\\u2192autophagy\\u2192NLRP3 inflammasome inflammation, and LOX to ROS-driven RANKL induction, nuclear localization in glioblastoma invasion, and miR-30a repression.\",\n      \"evidence\": \"LOX-1 siRNA/antibody with DNase II knockdown and NLRP3 assays; RANKL/RANK KO osteoclastogenesis; BAPN/siRNA in glioblastoma with localization IHC; miR-30a mimics in thyroid cancer models\",\n      \"pmids\": [\"24776598\", \"27606829\", \"25790191\", \"25488748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear import mechanism of LOX not defined\", \"Direct LOX nuclear DNA targets in glioblastoma not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved how LOX-1 ligand binding is structurally constrained and reciprocally coupled to PCSK9, and characterized cholesterol-dependent shedding of soluble LOX-1.\",\n      \"evidence\": \"Statin docking/MD and dimer-stabilization westerns on the CTLD; reciprocal siRNA and KO mouse studies of LOX-1/PCSK9 with mtROS modulation; M\\u03b2CD/statin shedding and exosome isolation experiments\",\n      \"pmids\": [\"25950192\", \"26092101\", \"26495844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Crystallographic confirmation of statin binding absent\", \"Identity of the shedding metalloproteinase not defined here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established LOX as a disease-causing aortic gene through catalytic-loss mutations and as a nuclear transactivator of SNAI2 driving EMT.\",\n      \"evidence\": \"Exome sequencing, family segregation, and enzymatic assays of LOX mutants; ChIP and promoter luciferase of LOX on SNAI2 with in vivo thyroid metastasis model\",\n      \"pmids\": [\"26838787\", \"27029493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How nuclear LOX is targeted to specific promoters unknown\", \"Relationship between secreted enzymatic LOX and nuclear LOX pool unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Confirmed direct miR-98 targeting of LOX-1 as a brake on foam-cell formation in atherosclerosis.\",\n      \"evidence\": \"3'-UTR luciferase reporter, miR-98 mimics/inhibitors in macrophages, agomiR/antagomiR-98 in ApoE-/- mice\",\n      \"pmids\": [\"29549823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single miRNA among broader regulatory network\", \"Tissue-specific delivery not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the proteolytic life cycle of LOX-1 controlling its atherogenic signaling, and placed HIF2A as the specific hypoxic driver of LOX-dependent fibrosis.\",\n      \"evidence\": \"ADAM10/SPPL2a/b substrate identification, TMD self-association, MAP kinase assays, SPPL2-deficient atherosclerosis mice; HIF2A shRNA/overexpression/inhibitor in orbital fibroblast organoids\",\n      \"pmids\": [\"30819724\", \"30388216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger of ligand-independent NTF signaling in vivo incompletely defined\", \"HIF1A-vs-HIF2A selectivity mechanism for LOX not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected LOX-1 turnover to E3 ligase control and tied LOX induction to ECM-driven chemoresistance and immune-cell signaling.\",\n      \"evidence\": \"HRD1-LOX-1 Co-IP, ubiquitination and KLF2 regulation in endothelium; LOX knockdown across organoids/xenografts/PDX with ITGA5/FN1/FAK-Src epistasis; Th17/Treg co-culture with pathway inhibitors and HF rat model\",\n      \"pmids\": [\"32308114\", \"32415208\", \"32649012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HRD1 ubiquitination sites on LOX-1 not mapped\", \"In vivo durability of LOX-targeted chemosensitization not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked LOX-driven matrix stiffening to mechanotransduction, showing it activates Piezo1 to induce GPX4-dependent ferroptosis in hypoxic-ischemic brain injury.\",\n      \"evidence\": \"ECM stiffness and LOX activity assays in HIBD models, Piezo1 analysis, pharmacological LOX/Piezo1 inhibition, GPX4 ferroptosis markers, behavioral testing\",\n      \"pmids\": [\"39260063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biophysical coupling of LOX cross-links to Piezo1 gating not measured\", \"Single-lab pathway requiring orthogonal confirmation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the secreted enzymatic, propeptide tumor-suppressor, and nuclear-transactivator activities of lysyl oxidase are partitioned and coordinated within a single gene product remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking catalytic, propeptide, and nuclear functions\", \"Mechanism of LOX nuclear import and promoter selection unknown\", \"Quantitative relationship between extracellular cross-linking and intracellular signaling pools undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [9, 13, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [1, 0]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 19]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [9, 13, 8]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 17, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [15, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [22, 10]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ITGA5\", \"FN1\", \"HRD1\", \"ADAM10\", \"SPPL2a\", \"PCSK9\", \"SNAI2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}